Necrostatin-34
CAS No. 375835-43-1
Necrostatin-34 ( 2-{[3-cyano-4-(4-methylphenyl)-6-oxo-1,4 )
Catalog No. M24335 CAS No. 375835-43-1
Necrostatin-34 is a RIPK1 kinase inhibitor, stabilizing RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 177 | In Stock |
|
| 10MG | 260 | In Stock |
|
| 25MG | 483 | In Stock |
|
| 50MG | 698 | In Stock |
|
| 100MG | 972 | In Stock |
|
| 500MG | 1953 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNecrostatin-34
-
NoteResearch use only, not for human use.
-
Brief DescriptionNecrostatin-34 is a RIPK1 kinase inhibitor, stabilizing RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.
-
DescriptionNecrostatin-34 is a RIPK1 kinase inhibitor, stabilizing RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.(In Vitro):Necrostatin-34 (Nec-34) exhibits IC50 values of 667 nM and 134 nM for TNFα in FADD def-Jurkat cells and L939 cells, respectively.Necrostatin-34 (Nec-34, 10?μM) inhibits the dimerization-induced RIPK1 activation as examined by phosphorylation of Ser166 (p-S166) of RIPK1, a biomarker for RIPK1 activation.Necrostatin-34 (Nec-34) may block TNFα-induced complex II formation by inhibiting the activation of RIPK1 kinase.
-
In VitroNecrostatin-34 (Nec-34) exhibits IC50 values of 667 nM and 134 nM for TNFα in FADD def-Jurkat cells and L939 cells, respectively.Necrostatin-34 (Nec-34, 10?μM) inhibits the dimerization-induced RIPK1 activation as examined by phosphorylation of Ser166 (p-S166) of RIPK1, a biomarker for RIPK1 activation.Necrostatin-34 (Nec-34) may block TNFα-induced complex II formation by inhibiting the activation of RIPK1 kinase. Western Blot Analysis Cell Line:RIPK1 knockout L929 cells transfected with an expressing vector encoding an inducible and dimerizable RIPK1 fused with FKBP at the C-terminus.Concentration:10?μM.Incubation Time:30 min (and then 100?ng/mL TNFα was added for indicated periods of time).Result:Downregulated p-S166 levels.
-
In Vivo——
-
Synonyms2-{[3-cyano-4-(4-methylphenyl)-6-oxo-1,4
-
PathwayApoptosis
-
TargetRIP kinase
-
RecptorRIPK1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number375835-43-1
-
Formula Weight384.48
-
Molecular FormulaC18H16N4O2S2
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (325.11 mM; Need ultrasonic)
-
SMILESO=C(NC1=NC=CS1)CSC2=C(C#N)C(C3=CC=C(C)C=C3)CC(N2)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huyan Meng, et al. Discovery of a cooperative mode of inhibiting RIPK1 kinase. Cell Discov. 2021 Jun 1;7(1):41.
molnova catalog
related products
-
WEHI-345
A potent and selective RIPK2 inhibitor with IC50/Kd of 130/46 nM; displays negligible activity (>10 uM) against RIPK1, RIPK4 and RIPK5.
-
GSK547
GSK547 (RIP1i, GSK 547) is a highly selective and potent inhibitor of RIP1 kinase that robustly targets RIP1 in vivo.
-
GSK-583
A potent, selective and orally bioavailable RIPK2 kinase inhibitor with IC50 of 5 nM and 2 nM for human and rat RIP2, respectively.
Cart
sales@molnova.com